Eiring, A M <br/><br/>
β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.  [electronic resource] 

 -  Leukemia  Dec 2015 
 - 2328-37 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/leu.2015.196  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Cadherins--physiology<br/>Cell Line, Tumor<br/>Drug Resistance, Neoplasm<br/>Fusion Proteins, bcr-abl--physiology<br/>Humans<br/>Imatinib Mesylate--therapeutic use<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Protein Kinase Inhibitors--therapeutic use<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Proto-Oncogene Proteins--physiology<br/>Wnt Proteins--physiology<br/>Wnt-5a Protein<br/>beta Catenin--physiology